BOSTON, Feb. 12, 2019 /PRNewswire/ -- CSOFT International, a global leader in cross-border communications, has announced the opening of its newest corporate office in Boston's Back Bay. Projecting to at least triple its life science business within the next 5 years, CSOFT aims to enable North American pharmaceutical companies achieve greater global success through a unique application of next-gen AI-powered language translation services and solutions.
"We're excited to be in Boston. The east coast, particularly Massachusetts, New Jersey, and North Carolina, is now the country's number one biotech hub for medical research and biopharma manufacturing," said CEO Shunee Yee. "As regulations and processes for clinical trials differ in each country, entering foreign markets effectively requires local knowledge and quality translations for global success," Yee commented further. Certificated in ISO 9001:2015 and ISO 13485:2016, CSOFT's dedicated life science business unit has over 15 years' of experience serving as a trusted provider in medical localization and clinical trial translations for top Biotech, Pharma, Diagnostics and Med Tech companies across all sectors throughout the healthcare industry.
As a strategic move to bridge the world's top two healthcare markets, CSOFT's Boston office will also serve as a regional hub to provide effective customer services and project execution to support its US med tech and pharma customers entering China's market. Among China's 1.4 billion population, more than 100 million people are diabetic and more than 300 million carry HBV. China is the 2nd largest Rx market in the world with 2018 alone showing healthcare expenditures totaling $800 billion USD.
The NMPA's (National Medical Products Administration) recent regulatory reform on accepting foreign clinical data and removing restrictions on approval application of imported drugs creates ample opportunities for global pharmaceutical companies. CSOFT has helped top US and European pharma companies successfully deliver more than a dozen drug submission applications for CFDA reviews and approvals.
"Drugs are needed in all corners of the world, and pharmaceutical companies need the language expertise to acknowledge the diversity not only in genetics but policies," said Richard Chin, Director of CSOFT's Life Science Business Unit.
"Despite the major policy changes to embrace innovation and harmonization using global standards, entering a market like China is still challenging. This is why finding the right local partner with in-depth knowledge and experience with CFDA policies is the key," remarked Dr. Grace Palma, CEO of ChinaMed Device, a Boston-based regulatory and commercial advisory firm who attended CSOFT's Boston opening.
CSOFT International is a leader in global communications services, providing turnkey solutions for companies facing the challenges of engaging customers and markets across linguistic and cultural barriers. With dual headquarters in San Francisco and Beijing, CSOFT maintains a worldwide presence across 16 different locations around the world, offering services from content creation to localization and translation in over 200 languages. With AI-powered tools, CSOFT guarantees efficient language solutions across all industry sectors. To learn more about CSOFT, please visit www.csoftintl.com
Nikki Andrews (U.S./Europe)
+1 (617) 263-8950
Tim Wang (Asia)
+86 21 5036 7600
SOURCE CSOFT International